Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath‐1H
- 6 April 2007
- journal article
- case report
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (4) , 917-919
Abstract
Immune‐mediated hemolytic anemia is a well‐recognized complication of hematopoietic stem cell transplantation. We report on a 6‐year‐old boy with X‐linked adrenoleukodystrophy who developed severe delayed alloimmune hemolytic anemia associated with immune‐mediated neutropenia and thrombocytopenia following major ABO incompatible unrelated cord blood transplantation. The patient's cytopenias were refractory to treatment with corticosteroids, cyclosporine, intravenous immune globulin, rituximab, and pentostatin. After one course of Campath‐1H his hematologic parameters normalized, suggesting that the compound may be an effective therapy for complex immunohematologic disorders complicating hematopoietic stem cell transplantation. The case also emphasizes the importance of T‐cells in transplant associated immune cytopenias. Pediatr Blood Cancer 2008;50:917–919.Keywords
This publication has 6 references indexed in Scilit:
- Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiologyAnnals of Hematology, 2006
- Management of Evans syndromeBritish Journal of Haematology, 2005
- Immune Hemolysis Associated With TransplantationSeminars in Hematology, 2005
- Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non‐malignant diseasesBritish Journal of Haematology, 2004
- The effect of treatment with Campath‐1H in patients with autoimmune cytopeniasBritish Journal of Haematology, 2001
- IMMUNOHEMATOLOGIC CONSEQUENCES OF MAJOR ABOMISMATCHED BONE MARROW TRANSPLANTATIONTransplantation, 1988